Moderna on Wednesday said it will soon request emergency use authorization for its COVID-19 vaccine for children under the age of six.
The company said it will be submitting data to the FDA “in the coming weeks,” The Hill reports.
Moderna said the vaccine was only about 44 percent effective at preventing symptomatic infection in children between the ages of 6 months and two years old, and 37 percent effective in children between two and five.
Children in the trial received a two-dose series of the vaccine at a quarter of the size of the normal adult dose.
“We believe these latest results from the KidCOVE study are good news for parents of children under 6 years of age. We now have clinical data on the performance of our vaccine from infants six months of age through older adults,” Stéphane Bancel, Chief Executive Officer of Moderna said in a statement.
“Given the need for a vaccine against COVID-19 in infants and young children we are working with the U.S. FDA and regulators globally to submit these data as soon as possible,” he continued.
Moderna also said it will update its data and ask the FDA to clear larger doses for children ages 6 to 11.
